ASP Isotopes Inc.ASPI

NasdaqMaterialsMiscellaneous Chemical Products
Price (close)
$2.92
Market cap
$380.7M
P/E
—
Revenue (TTM)
$30.9M
Net income
-$117.3M
Dividend yield
—
1-year total return
-72.6%
Net margin
-380.3%
Revenue growth
573.4%
Debt / equity
0.23x

What ASP Isotopes Inc. does.

We are an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. In addition, in January 2026, we acquired Renergen, which is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG (as discussed further below). Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus with respect to our isotope enrichment platform is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”).

We commenced commercial production of enriched isotopes at both of our ASP enrichment facilities located in Pretoria, South Africa during the first half of 2025. Our first ASP enrichment facility is designed to enrich light isotopes, such as C-14 and C-12. The second ASP enrichment facility, which is substantially larger than the first, should have the potential to enrich kilogram quantities of relatively heavier isotopes, including but not limited to Si-28. We are targeting initial commercial shipments of enriched C-14 in mid-2026. We are targeting initial commercial shipments of enriched Si-28 during the second quarter of 2026. We have also completed the commissioning phase and are producing commercial samples of highly enriched Yb-176 at our third enrichment facility, a QE technology facility, which is our first laser-based enrichment plant. We are targeting initial commercial shipments of Yb-176 in mid-2026 or the third quarter of 2026.

Revenue and profit, by fiscal year.

Fiscal year20212022202320242025
Revenue—$0$433,026$4.1M$23.8M
Net income—-$4.9M-$16.3M-$32.4M-$159.8M
Free cash flow—-$7.4M-$7.7M-$26.4M-$47.4M

More on ASPI.

Figures from ASP Isotopes Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.